文献速递胸部肿瘤

曲妥珠单抗美坦新用于人表皮生长因子受体2外显子20插入突变阳性非小细胞肺癌患者

Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
PubMed 文献 · Eur J Cancer · 2021-12-24

该II期研究评估了曲妥珠单抗美坦新(T-DM1)在HER2外显子20插入突变阳性非小细胞肺癌患者中的疗效。2019年2月至2020年7月共入组22例,客观缓解率为38.1%(90%置信区间23.0-55.9%),疾病控制率为52.4%,中位无进展生存期2.8个月,中位总生存期8.1个月。结论认为T-DM1是潜在治疗选择,但需进一步研究生物标志物以改善疗效。

要点

  • T-DM1每21天静脉给药3.6 mg/kg,用于HER2外显子20插入突变阳性且接受过一或两线化疗的非小细胞肺癌患者。
  • 22例患者中客观缓解率为38.1%(90%置信区间23.0-55.9%),疾病控制率为52.4%。
  • 中位缓解持续时间3.5个月,中位无进展生存期2.8个月,中位总生存期8.1个月,≥3级不良事件频率低。

核心结论

  • T-DM1是HER2外显子20插入突变非小细胞肺癌患者的潜在治疗选择。
  • 作者认为需进一步研究T-DM1的生物标志物以改善其对该类突变非小细胞肺癌的疗效。

研究设计与样本

  • II期研究,入组经下一代测序或多重聚合酶链反应平台确认HER2外显子20插入突变且有1或2线化疗史的非小细胞肺癌患者。
  • 患者接受T-DM1 3.6 mg/kg静脉给药,每21天一次。
  • 主要终点为客观缓解率,2019年2月至2020年7月共入组22例患者。

主要发现

  • A775_G776insYVMA是最常见的HER2外显子20插入突变,占22例患者中的19例(86.4%)。
  • 客观缓解率为38.1%(90%置信区间23.0-55.9%),疾病控制率为52.4%。
  • 中位缓解持续时间为3.5个月,中位无进展生存期为2.8个月,中位总生存期为8.1个月。
  • 毒性轻微,≥3级不良事件频率低。

关键数值与推荐

  • T-DM1给药方案为3.6 mg/kg静脉给药,每21天一次。
  • 客观缓解率38.1%(90%置信区间23.0-55.9%),疾病控制率52.4%。
  • 中位缓解持续时间3.5个月,中位无进展生存期2.8个月,中位总生存期8.1个月。

临床怎么用

  • 作者认为T-DM1是HER2外显子20插入突变非小细胞肺癌患者的潜在治疗选择。
  • 作者认为需进一步研究T-DM1的生物标志物以改善其疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) mutations are present in ∼3% of patients with non-small cell lung cancer (NSCLC), with exon-20 insertions accounting for ∼90% of such HER2 mutations and having been identified as driver oncogenic alterations. Antibody-cytotoxic drug conjugates including trastuzumab deruxtecan have shown an excellent efficacy for NSCLC with HER2 mutations. We have now performed a phase II study to evaluate the efficacy of ado-trastuzumab emtansine (T-DM1) for NSCLC positive for HER2 exon-20 insertion mutations. PATIENTS AND METHODS: Eligible patients with HER2 exon-20 insertion mutations confirmed by next-generation sequencing or multiplex polymerase chain reaction platforms and a history of one or two lines of chemotherapy received T-DM1 (3.6 mg/kg) intravenously every 21 days. The primary end-point of the study was the objective response rate (ORR). RESULTS: Between February 2019 and July 2020, 22 patients were enrolled in the study. A775_G776insYVMA was the most frequent HER2 exon-20 insertion mutation, accounting for 19 (86.4%) of the 22 patients. The ORR was 38.1% (90% confidence interval, 23.0-55.9%), and the disease control rate was 52.4%. The median duration of response was 3.5 months, and the median progression-free survival and median overall survival were 2.8 and 8.1 months, respectively. Toxicity was mild, with the frequency of adverse events of grade ≥3 being low. CONCLUSION: T-DM1 is a potential treatment option for patients with NSCLC with HER2 exon-20 insertion mutations. Further investigation of biomarkers for T-DM1 is warranted to improve its efficacy for NSCLC with such mutations. CLINICAL TRIAL NUMBER: JapicCTI-194620.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Iwama E, Zenke Y, Sugawara S, et al. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. Eur J Cancer. 2021. PMID: 34959152. doi:10.1016/j.ejca.2021.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。